SCHEMBL30889602

SCHEMBL30889602

Fc1ccc(Cl)nc1SCc1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.42
CYP2C9 P11712 2/20 0.42
METAP1 P53582 1/20 0.41
HTT P42858 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
HSD17B10 Q99714 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
PPARG P37231 1/20 0.40
DRD2 P14416 1/20 0.40
TBXA2R P21731 1/20 0.40
CTSB P07858 1/20 0.40
LMNA P02545 2/20 0.40
EGFR P00533 1/20 0.39
MAPT P10636 2/20 0.39
METAP2 P50579 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17648740 0.83 HSD17B10 (0.43) ALDH1A1CYP2C9HTTTDP1HSD17B10
SCHEMBL21244672 0.80 ALDH1A1 (0.51) ALDH1A1CYP2C9METAP1HTTTDP1
SCHEMBL26662403 0.80 ALDH1A1 (0.42) ALDH1A1CYP2C9METAP1HTTTDP1
SCHEMBL30928671 0.80 ALDH1A1 (0.51) ALDH1A1METAP1HTTTDP1HSD17B10
SCHEMBL30821924 0.77 POLB (0.44) HSD17B10SMN1; SMN2NPC1RAB9ADRD2
SCHEMBL22280430 0.74 MEN1 (0.62) ALDH1A1CYP2C9HTTCTSBLMNA
SCHEMBL30646274 0.72 ALDH1A1 (0.59) ALDH1A1CYP2C9METAP1HTTTDP1
SCHEMBL9364221 0.71 ALDH1A1 (0.47) ALDH1A1CYP2C9METAP1HTTTDP1
SCHEMBL31735945 0.71 LMNA (0.48) ALDH1A1CYP2C9METAP1HTTTDP1
SCHEMBL30821620 0.69 KCNQ3 (0.44) ALDH1A1CYP2C9HTTHSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4611899-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE Petra Pharma Corporation (US) 2025-09-10 EP disclosed
US-20250206752-A1 PI3K INHIBITORS COGENT BIOSCIENCES, INC. 2025-06-26 US disclosed
US-12281122-B1 PI3K inhibitors COGENT BIOSCIENCES, INC. (US) 2025-04-22 US disclosed
WO-2025029683-A1 PI3K INHIBITORS COGENT BIOSCIENCES, INC. (US) 2025-02-06 WO disclosed
US-20240182460-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE PETRA PHARMA CORPORATION 2024-06-06 US disclosed
WO-2024097172-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE PETRA PHARMA CORPORATION (US) 2024-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250206752-A1 PI3K INHIBITORS PIK3CA, PIK3R5, PIK3R4 ALDH1A1 4448/4885CYP2C9 1556/4885METAP1 4068/4885
US-12281122-B1 PI3K inhibitors PIK3CA, PIK3R5, PIK3R4 ALDH1A1 4448/4885CYP2C9 1556/4885METAP1 4068/4885
US-20240182460-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE PIK3CA, PIK3R4, PIK3R5 ALDH1A1 3403/4885CYP2C9 822/4885METAP1 4858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.